Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $26.76M by Medicaid between Jan 2018 and Dec 2024, across 268 billing codes. Its largest line is 99284, emergency room visit (serious) — 21% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
SOUTH WILLIAMSON, KY 41503
SOUTH WILLIAMSON, KY 41503
33aNPI1649270257assigned 07/26/2005
33bProvider typeOccupational Therapist
28Total paid$26.76M
24GClaims634,902
24DCodes billed268
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Occupational Therapist providers in Kentucky
Rank by total paid#2 of 71
Median peer was paid$94K
This provider vs. median286×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 106,532 | $4.93M | |
| 2019 | 79,808 | $4.06M | |
| 2020 | 106,587 | $5.28M | |
| 2021 | 121,195 | $3.63M | |
| 2022 | 83,354 | $2.91M | |
| 2023 | 75,902 | $3.00M | |
| 2024incomplete | 61,524 | $2.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 23,811 | 20,833 | $5.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 5,308 | 4,190 | $2.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.0% | 23,357 | 20,682 | $1.86M |
| G0378 | Hospital observation service, per hour | 4.1% | 3,238 | 1,822 | $1.10M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.8% | 3,009 | 2,726 | $1.02M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,100 | 1,854 | $972K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 14,048 | 3,118 | $792K |
| 80053 | Comprehensive metabolic panel | 2.4% | 43,626 | 32,185 | $647K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 3,875 | 3,385 | $489K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 1,985 | 1,758 | $483K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 43,141 | 34,653 | $436K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 7,618 | 6,756 | $380K |
256 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 7,887 | $332K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 7,488 | $332K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 54,570 | $310K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 12,268 | $283K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 16,230 | $278K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 6,158 | $276K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,964 | $256K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,537 | $253K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 849 | $246K |
| 84484 | <1% | 10,388 | $242K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,493 | $238K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,032 | $237K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 952 | $232K |
| 72131 | <1% | 1,047 | $220K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,018 | $216K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 494 | $203K |
| 80061 | Lipid panel | <1% | 9,165 | $196K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,713 | $193K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,118 | $189K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,429 | $183K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,162 | $181K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,933 | $180K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,628 | $169K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 19,707 | $165K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,501 | $160K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 4,428 | $158K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,436 | $152K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,434 | $150K |
| 81001 | <1% | 18,281 | $147K | |
| 87631 | <1% | 1,465 | $128K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,985 | $128K |
| 87040 | <1% | 5,570 | $126K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,067 | $122K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,028 | $119K |
| 82607 | <1% | 5,216 | $113K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 847 | $113K |
| 97035 | <1% | 3,295 | $111K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 233 | $107K |
| 93017 | <1% | 954 | $104K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,939 | $94K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,812 | $92K |
| 83880 | <1% | 3,561 | $91K | |
| 73562 | <1% | 1,728 | $87K | |
| 83735 | <1% | 6,944 | $86K | |
| 96376 | <1% | 2,795 | $84K | |
| 82150 | <1% | 3,192 | $82K | |
| 73630 | <1% | 2,134 | $79K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 423 | $79K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,386 | $78K |
| 82553 | <1% | 3,448 | $77K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 971 | $76K |
| 76830 | Ultrasound, transvaginal | <1% | 832 | $76K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,397 | $74K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,790 | $67K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,167 | $67K |
| 82550 | <1% | 4,870 | $63K | |
| 73030 | <1% | 1,875 | $59K | |
| 82652 | <1% | 2,074 | $56K | |
| 73610 | <1% | 1,385 | $56K | |
| 83690 | <1% | 3,972 | $53K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,780 | $48K |
| 97014 | <1% | 1,739 | $45K | |
| 84439 | <1% | 2,542 | $45K | |
| 78454 | <1% | 76 | $45K | |
| 72110 | <1% | 707 | $44K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,228 | $44K |
| 85027 | <1% | 4,300 | $43K | |
| 76536 | <1% | 547 | $42K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 123 | $42K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,776 | $41K |
| 85730 | <1% | 3,641 | $39K | |
| 96367 | <1% | 1,382 | $35K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 878 | $35K |
| 72100 | <1% | 887 | $34K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,641 | $34K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,367 | $33K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,115 | $33K |
| 97161 | <1% | 683 | $32K | |
| 85610 | <1% | 4,224 | $32K | |
| 73130 | <1% | 855 | $32K | |
| 74018 | <1% | 800 | $31K | |
| 84703 | <1% | 1,407 | $31K | |
| 84702 | <1% | 982 | $31K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 234 | $30K |
| 80171 | <1% | 1,164 | $29K | |
| 81025 | <1% | 3,660 | $27K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 188 | $26K |
| 87186 | <1% | 1,912 | $26K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,101 | $25K |
| 73110 | <1% | 571 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,103 | $22K |
| 83540 | <1% | 2,119 | $21K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 685 | $21K |
| 82728 | <1% | 1,089 | $21K | |
| 83550 | <1% | 1,515 | $19K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 755 | $17K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,440 | $16K |
| 80076 | <1% | 1,184 | $16K | |
| 87076 | <1% | 1,210 | $14K | |
| 93971 | <1% | 191 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 870 | $14K |
| 80074 | <1% | 310 | $13K | |
| 96368 | <1% | 578 | $13K | |
| 82746 | <1% | 578 | $13K | |
| 87077 | <1% | 994 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 42 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 286 | $11K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 327 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 44 | $10K |
| 97162 | <1% | 207 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 612 | $10K |
| 87634 | <1% | 200 | $10K | |
| 72050 | <1% | 168 | $10K | |
| J3490 | Unclassified drugs | <1% | 881 | $10K |
| 74022 | <1% | 157 | $10K | |
| 83605 | <1% | 1,130 | $10K | |
| 80299 | <1% | 190 | $9K | |
| 93041 | <1% | 529 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 105 | $9K |
| 72128 | <1% | 33 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 610 | $9K |
| 85378 | <1% | 1,001 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 789 | $9K |
| 73502 | <1% | 344 | $9K | |
| 0100U | <1% | 255 | $8K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 449 | $8K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $8K |
| 84550 | <1% | 916 | $8K | |
| 85379 | <1% | 240 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 176 | $7K |
| 82043 | <1% | 624 | $7K | |
| 82803 | <1% | 235 | $6K | |
| 73090 | <1% | 256 | $6K | |
| 97116 | <1% | 290 | $6K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 563 | $6K |
| 86677 | <1% | 171 | $6K | |
| 86803 | <1% | 412 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 239 | $6K |
| 84100 | <1% | 211 | $6K | |
| 84436 | <1% | 242 | $6K | |
| 70486 | <1% | 27 | $6K | |
| 87070 | <1% | 370 | $6K | |
| 85652 | <1% | 857 | $6K | |
| 86756 | <1% | 214 | $6K | |
| A9270 | Non-covered item or service | <1% | 1,056 | $5K |
| 0012A | <1% | 369 | $5K | |
| 84481 | <1% | 203 | $5K | |
| 86900 | <1% | 499 | $5K | |
| 86901 | <1% | 469 | $5K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 136 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 204 | $5K |
| 86787 | <1% | 132 | $4K | |
| 88142 | <1% | 196 | $4K | |
| 36600 | <1% | 220 | $4K | |
| 0011A | <1% | 414 | $4K | |
| 73590 | <1% | 134 | $4K | |
| 88312 | <1% | 75 | $4K | |
| 86850 | <1% | 412 | $4K | |
| 93880 | <1% | 15 | $4K | |
| 73080 | <1% | 128 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 870 | $3K |
| 12001 | <1% | 59 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 508 | $3K |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 232 | $3K |
| 86376 | <1% | 253 | $3K | |
| 72070 | <1% | 54 | $3K | |
| 90715 | <1% | 100 | $3K | |
| 90714 | <1% | 114 | $3K | |
| 80143 | <1% | 208 | $2K | |
| 86140 | <1% | 264 | $2K | |
| 86038 | <1% | 187 | $2K | |
| 82565 | <1% | 75 | $2K | |
| 0002A | <1% | 139 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 70 | $2K |
| 86800 | <1% | 54 | $2K | |
| 84480 | <1% | 70 | $2K | |
| 83013 | <1% | 24 | $2K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 12 | $2K |
| 90662 | <1% | 73 | $2K | |
| 84146 | <1% | 77 | $2K | |
| 99406 | <1% | 385 | $2K | |
| 81002 | <1% | 699 | $2K | |
| 12002 | <1% | 24 | $2K | |
| 83001 | <1% | 78 | $2K | |
| 99218 | <1% | 307 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 42 | $2K |
| 87581 | <1% | 42 | $2K | |
| 87486 | <1% | 42 | $2K | |
| 86592 | <1% | 248 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 68 | $1K |
| 87340 | <1% | 133 | $1K | |
| 80179 | <1% | 90 | $1K | |
| 0001A | <1% | 143 | $1K | |
| 82947 | <1% | 158 | $1K | |
| 87807 | <1% | 136 | $1K | |
| 76642 | <1% | 41 | $1K | |
| 59025 | Fetal non-stress test | <1% | 67 | $1K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 27 | $1K |
| 82105 | <1% | 42 | $1K | |
| 86762 | <1% | 64 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $1K |
| 77080 | <1% | 13 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 51 | $1K |
| 83002 | <1% | 48 | $1K | |
| 71101 | <1% | 26 | $936.49 | |
| 73552 | <1% | 28 | $892.82 | |
| 97165 | <1% | 20 | $857.87 | |
| 82310 | <1% | 15 | $799.68 | |
| 86738 | <1% | 90 | $769.20 | |
| 82677 | <1% | 29 | $706.94 | |
| 86200 | <1% | 68 | $701.32 | |
| 80177 | <1% | 69 | $696.93 | |
| 76770 | <1% | 13 | $667.71 | |
| 87590 | <1% | 31 | $603.88 | |
| 84153 | <1% | 26 | $555.64 | |
| 73120 | <1% | 14 | $553.86 | |
| 10060 | <1% | 17 | $541.66 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 43 | $512.14 |
| 86336 | <1% | 29 | $482.08 | |
| 86431 | <1% | 95 | $458.06 | |
| 84403 | <1% | 32 | $442.85 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 29 | $409.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 54 | $376.75 |
| 82670 | <1% | 13 | $327.24 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 20 | $306.06 |
| 82009 | <1% | 48 | $291.30 | |
| 83615 | <1% | 25 | $279.54 | |
| G0008 | Administration of influenza virus vaccine | <1% | 15 | $277.37 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 81 | $251.44 |
| 80184 | <1% | 28 | $249.61 | |
| 94760 | <1% | 28 | $233.20 | |
| 84402 | <1% | 18 | $231.80 | |
| 88304 | <1% | 13 | $231.41 | |
| 73060 | <1% | 12 | $228.03 | |
| 82140 | <1% | 18 | $225.30 | |
| 80050 | General health panel | <1% | 14 | $217.44 |
| 84270 | <1% | 16 | $213.71 | |
| 99499 | <1% | 15 | $190.80 | |
| 51702 | <1% | 16 | $190.02 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 12 | $167.32 |
| 80161 | <1% | 15 | $140.00 | |
| 82248 | <1% | 15 | $118.50 | |
| 82570 | <1% | 29 | $116.24 | |
| 90686 | <1% | 33 | $92.20 | |
| 86308 | <1% | 14 | $81.02 | |
| J9219 | Leuprolide acetate implant, 65 mg | <1% | 20 | $79.07 |
| 81003 | <1% | 15 | $52.80 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 46 | $35.78 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 13 | $26.60 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 38 | $25.40 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 15 | $21.63 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 29 | $15.88 |
| 80346 | 0% | 14 | $0.00 | |
| 80345 | 0% | 14 | $0.00 | |
| 80320 | 0% | 14 | $0.00 | |
| 91301 | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.